Medpace Holdings, Inc. (NASDAQ:MEDP) Given Average Recommendation of “Hold” by Analysts

Medpace Holdings, Inc. (NASDAQ:MEDP) has earned an average recommendation of “Hold” from the seventeen ratings firms that are presently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a sell rating, ten have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $487.1818.

Several brokerages have commented on MEDP. Mizuho raised their price target on shares of Medpace from $575.00 to $655.00 and gave the company an “outperform” rating in a report on Friday, October 24th. Rothschild & Co Redburn cut Medpace from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $342.00 to $474.00 in a research report on Wednesday, September 3rd. Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. TD Cowen raised their price target on Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a report on Friday, October 24th. Finally, Rothschild Redb downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 3rd.

Medpace Trading Down 0.7%

Shares of NASDAQ:MEDP opened at $583.70 on Wednesday. The stock has a market cap of $16.44 billion, a PE ratio of 40.82, a price-to-earnings-growth ratio of 2.67 and a beta of 1.42. The stock’s fifty day simple moving average is $564.15 and its two-hundred day simple moving average is $449.46. Medpace has a 1-year low of $250.05 and a 1-year high of $626.26.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. The business had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm’s quarterly revenue was up 23.7% compared to the same quarter last year. During the same quarter last year, the company posted $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, sell-side analysts forecast that Medpace will post 12.29 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, VP Susan E. Burwig sold 20,000 shares of Medpace stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $609.15, for a total value of $12,183,000.00. Following the transaction, the vice president owned 27,500 shares in the company, valued at approximately $16,751,625. The trade was a 42.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Kevin M. Brady sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $590.35, for a total value of $1,771,050.00. Following the completion of the sale, the chief financial officer owned 6,000 shares of the company’s stock, valued at $3,542,100. The trade was a 33.33% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 364,079 shares of company stock valued at $219,241,718 over the last quarter. 20.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Medpace

Several hedge funds have recently made changes to their positions in MEDP. IFP Advisors Inc increased its holdings in Medpace by 157.2% in the 3rd quarter. IFP Advisors Inc now owns 499 shares of the company’s stock worth $257,000 after buying an additional 305 shares in the last quarter. Swiss Life Asset Management Ltd boosted its holdings in shares of Medpace by 70.3% during the 3rd quarter. Swiss Life Asset Management Ltd now owns 1,129 shares of the company’s stock valued at $580,000 after acquiring an additional 466 shares during the last quarter. CIBC Bancorp USA Inc. bought a new stake in shares of Medpace in the third quarter worth approximately $283,000. Ariadne Wealth Management LP bought a new stake in shares of Medpace in the third quarter worth approximately $244,000. Finally, Wilmington Savings Fund Society FSB raised its holdings in shares of Medpace by 124.1% during the third quarter. Wilmington Savings Fund Society FSB now owns 130 shares of the company’s stock valued at $67,000 after purchasing an additional 72 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.